Roche German Unit Back To Norm

20 March 1995

Hoffmann-La Roche's German subsidiary reverted to normal expansion in 1994, after a downturn in 1993. Total sales of the unit improved by 11% to 1.2 billion Deutschemarks ($853.2 million), and 1995 sales are projected at over 1.3 billion marks. Drugs accounted for 60% of turnover.

Roche says that while prices remain depressed, the prescribing of innovative drugs by German doctors has recovered, and adds that a series of new launches have contributed to higher volume, especially in the case of the genetically-engineered cystic fibrosis drug Pulmozyme (dornase alfa) and the antibiotic Globocef (cefetamet pivoxil).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight